Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance

David L. H. Chan; Nick Pavlakis; Geoffrey P. Schembri; Elizabeth J. Bernard; Edward Hsiao; Aimee Hayes; Tristan Barnes; Connie Diakos; Mustafa Khasraw; Jaswinder Samra; Enid Eslick; Paul J. Roach; Alexander Engel; Stephen J. Clarke; Dale L. Bailey

doi:10.7150/thno.18068

Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance

David L. H. Chan, Nick Pavlakis, Geoffrey P. Schembri, Elizabeth J. Bernard, Edward Hsiao, Aimee Hayes, Tristan Barnes, Connie Diakos, Mustafa Khasraw, Jaswinder Samra, Enid Eslick, Paul J. Roach, Alexander Engel, Stephen J. Clarke, Dale L. Bailey^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

225 Citations (Scopus)

54 Downloads (Pure)

Abstract

Background: PET scans using FDG and somatostatin receptor imaging agents have both been used to study neuroendocrine tumours. Most reports have documented the sensitivity and specificity of each radiopharmaceutical independently, and even suggested the superiority of one over the other for different grades of disease. Aim: The aim of this work was to develop a grading scheme that describes the joint results of both the FDG and somatostatin receptor imaging PET scans in staging subjects with neuroendocrine tumours in a single combined parameter. The grading scheme that has been developed is referred to as the NETPET grade.

Methods: This is a retrospective study which assessed subjects who had both FDG and somatostatin receptor PET imaging at our institution within 31 days of each other. The NETPET grade was assigned by experienced nuclear medicine physicians and compared with other clinical data such as WHO grade and overall survival.

Results: In the period 2011-2015 we were able to recruit 62 subjects with histologically proven metastatic neuroendocrine tumour for review. The NETPET grade incorporating both the FDG and somatostatin receptor imaging results was significantly correlated with overall survival by univariate analysis (p=0.0018), whereas in this cohort the WHO grade at the time of diagnosis did not correlate with survival.

Conclusions: The NETPET grade has promise as a prognostic imaging biomarker in neuroendocrine tumours. It permits the capturing of the complexity of dual radiotracer imaging in a single parameter which describes the subjects' disease and is readily amenable to use in patient management and further research.

Original language	English
Pages (from-to)	1149-1158
Number of pages	10
Journal	Theranostics
Volume	7
Issue number	5
DOIs	https://doi.org/10.7150/thno.18068
Publication status	Published - 2017
Externally published	Yes

Bibliographical note

Copyright the Publisher. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

PET scans
Neuroendocrine tumour

Access to Document

10.7150/thno.18068Licence: CC BY-NC

Publisher version (open access)Final published version, 1.46 MBLicence: CC BY-NC

Cite this

Chan, D. L. H., Pavlakis, N., Schembri, G. P., Bernard, E. J., Hsiao, E., Hayes, A., Barnes, T., Diakos, C., Khasraw, M., Samra, J., Eslick, E., Roach, P. J., Engel, A., Clarke, S. J., & Bailey, D. L. (2017). Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics, 7(5), 1149-1158. https://doi.org/10.7150/thno.18068

@article{c3b39cad4bb341b2aec9a8b06950904a,

title = "Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance",

abstract = "Background: PET scans using FDG and somatostatin receptor imaging agents have both been used to study neuroendocrine tumours. Most reports have documented the sensitivity and specificity of each radiopharmaceutical independently, and even suggested the superiority of one over the other for different grades of disease. Aim: The aim of this work was to develop a grading scheme that describes the joint results of both the FDG and somatostatin receptor imaging PET scans in staging subjects with neuroendocrine tumours in a single combined parameter. The grading scheme that has been developed is referred to as the NETPET grade. Methods: This is a retrospective study which assessed subjects who had both FDG and somatostatin receptor PET imaging at our institution within 31 days of each other. The NETPET grade was assigned by experienced nuclear medicine physicians and compared with other clinical data such as WHO grade and overall survival. Results: In the period 2011-2015 we were able to recruit 62 subjects with histologically proven metastatic neuroendocrine tumour for review. The NETPET grade incorporating both the FDG and somatostatin receptor imaging results was significantly correlated with overall survival by univariate analysis (p=0.0018), whereas in this cohort the WHO grade at the time of diagnosis did not correlate with survival. Conclusions: The NETPET grade has promise as a prognostic imaging biomarker in neuroendocrine tumours. It permits the capturing of the complexity of dual radiotracer imaging in a single parameter which describes the subjects' disease and is readily amenable to use in patient management and further research.",

keywords = "PET scans, Neuroendocrine tumour",

author = "Chan, {David L. H.} and Nick Pavlakis and Schembri, {Geoffrey P.} and Bernard, {Elizabeth J.} and Edward Hsiao and Aimee Hayes and Tristan Barnes and Connie Diakos and Mustafa Khasraw and Jaswinder Samra and Enid Eslick and Roach, {Paul J.} and Alexander Engel and Clarke, {Stephen J.} and Bailey, {Dale L.}",

note = "Copyright the Publisher. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2017",

doi = "10.7150/thno.18068",

language = "English",

volume = "7",

pages = "1149--1158",

journal = "Theranostics",

issn = "1838-7640",

publisher = "Ivyspring International Publisher",

number = "5",

}

Chan, DLH, Pavlakis, N, Schembri, GP, Bernard, EJ, Hsiao, E, Hayes, A, Barnes, T, Diakos, C, Khasraw, M, Samra, J, Eslick, E, Roach, PJ, Engel, A, Clarke, SJ & Bailey, DL 2017, 'Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance', Theranostics, vol. 7, no. 5, pp. 1149-1158. https://doi.org/10.7150/thno.18068

TY - JOUR

T1 - Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours

T2 - proposal for a novel grading scheme with prognostic significance

AU - Chan, David L. H.

AU - Pavlakis, Nick

AU - Schembri, Geoffrey P.

AU - Bernard, Elizabeth J.

AU - Hsiao, Edward

AU - Hayes, Aimee

AU - Barnes, Tristan

AU - Diakos, Connie

AU - Khasraw, Mustafa

AU - Samra, Jaswinder

AU - Eslick, Enid

AU - Roach, Paul J.

AU - Engel, Alexander

AU - Clarke, Stephen J.

AU - Bailey, Dale L.

N1 - Copyright the Publisher. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2017

Y1 - 2017

N2 - Background: PET scans using FDG and somatostatin receptor imaging agents have both been used to study neuroendocrine tumours. Most reports have documented the sensitivity and specificity of each radiopharmaceutical independently, and even suggested the superiority of one over the other for different grades of disease. Aim: The aim of this work was to develop a grading scheme that describes the joint results of both the FDG and somatostatin receptor imaging PET scans in staging subjects with neuroendocrine tumours in a single combined parameter. The grading scheme that has been developed is referred to as the NETPET grade. Methods: This is a retrospective study which assessed subjects who had both FDG and somatostatin receptor PET imaging at our institution within 31 days of each other. The NETPET grade was assigned by experienced nuclear medicine physicians and compared with other clinical data such as WHO grade and overall survival. Results: In the period 2011-2015 we were able to recruit 62 subjects with histologically proven metastatic neuroendocrine tumour for review. The NETPET grade incorporating both the FDG and somatostatin receptor imaging results was significantly correlated with overall survival by univariate analysis (p=0.0018), whereas in this cohort the WHO grade at the time of diagnosis did not correlate with survival. Conclusions: The NETPET grade has promise as a prognostic imaging biomarker in neuroendocrine tumours. It permits the capturing of the complexity of dual radiotracer imaging in a single parameter which describes the subjects' disease and is readily amenable to use in patient management and further research.

AB - Background: PET scans using FDG and somatostatin receptor imaging agents have both been used to study neuroendocrine tumours. Most reports have documented the sensitivity and specificity of each radiopharmaceutical independently, and even suggested the superiority of one over the other for different grades of disease. Aim: The aim of this work was to develop a grading scheme that describes the joint results of both the FDG and somatostatin receptor imaging PET scans in staging subjects with neuroendocrine tumours in a single combined parameter. The grading scheme that has been developed is referred to as the NETPET grade. Methods: This is a retrospective study which assessed subjects who had both FDG and somatostatin receptor PET imaging at our institution within 31 days of each other. The NETPET grade was assigned by experienced nuclear medicine physicians and compared with other clinical data such as WHO grade and overall survival. Results: In the period 2011-2015 we were able to recruit 62 subjects with histologically proven metastatic neuroendocrine tumour for review. The NETPET grade incorporating both the FDG and somatostatin receptor imaging results was significantly correlated with overall survival by univariate analysis (p=0.0018), whereas in this cohort the WHO grade at the time of diagnosis did not correlate with survival. Conclusions: The NETPET grade has promise as a prognostic imaging biomarker in neuroendocrine tumours. It permits the capturing of the complexity of dual radiotracer imaging in a single parameter which describes the subjects' disease and is readily amenable to use in patient management and further research.

KW - PET scans

KW - Neuroendocrine tumour

UR - http://www.scopus.com/inward/record.url?scp=85014711491&partnerID=8YFLogxK

U2 - 10.7150/thno.18068

DO - 10.7150/thno.18068

M3 - Article

C2 - 28435454

AN - SCOPUS:85014711491

SN - 1838-7640

VL - 7

SP - 1149

EP - 1158

JO - Theranostics

JF - Theranostics

IS - 5

ER -

Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this